Disappointing Data for Bowel Resection Drug Sink Tranzyme
By Catherine Shaffer
Tuesday, March 13, 2012
Tranzyme Pharma Inc.'s drug ulimorelin failed to perform in a trial for bowel resection recovery acceleration, according to top-line results released Monday.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.